With the advancement of transfusion medicine and the widespread use of platelet-related preparations, platelet transfusion has become a critical therapeutic intervention in clinics. To enhance the safety and efficacy of platelet transfusion, platelet blood group typing has been increasingly implemented in clinical practice, accompanied by the emergence of novel testing technologies and methodologies, such as flow cytometric immuno-bead array analysis, microtiter plate-based immobilized recombinant single antigen enzyme-linked immunosorbent assay and third-generation sequencing. Significant progress has been made in platelet blood group detection, including improvements in serological testing methods, integration and optimization of multi-platform detection technologies, and the development of high-throughput molecular genotyping techniques. The advancement in platelet blood group detection technology has significantly enhanced detection precision and clinical applicability, providing an important support for transfusion safety, managing platelet-related diseases, and developing antiplatelet drugs.

With the advancement of transfusion medicine and the widespread use of platelet-related preparations, platelet transfusion has become a critical therapeutic intervention in clinics. To enhance the safety and efficacy of platelet transfusion, platelet blood group typing has been increasingly implemented in clinical practice, accompanied by the emergence of novel testing technologies and methodologies, such as flow cytometric immuno-bead array analysis, microtiter plate-based immobilized recombinant single antigen enzyme-linked immunosorbent assay and third-generation sequencing. Significant progress has been made in platelet blood group detection, including improvements in serological testing methods, integration and optimization of multi-platform detection technologies, and the development of high-throughput molecular genotyping techniques. The advancement in platelet blood group detection technology has significantly enhanced detection precision and clinical applicability, providing an important support for transfusion safety, managing platelet-related diseases, and developing antiplatelet drugs.

Objective To discuss the effects and the complications of partial splenic artery embolization with gelatin sponge or with lipiodol for hypersplenism,to provide scientific information helpful for the selection of embolization materials in clinical practice.Methods Partial splenic artery embolization with gelatin sponge was performed in forty patients with hypersplenism due to cirrhosis(gelatin sponge group)and partial splenic artery embolization with lipiodol was carried out in another thirty-nine patients(lipiodol group).The clinical data were retrospectively analyzed.The laboratory studies,complications and recurrence were observed and compared between two groups.Results No significant difference in the reduction of splenic size,in the hemoglobin levels and in the thrombocyte and leucocyte counts existed between two groups(P＞0.05).However,the platelet count in lipiodol group was obviously decreased three months after the treatment.The occurrence of complications in gelatin sponge group was much higher than that in lipiodol group(P＜0.05).The toxic reaction of the liver and gastrointestinal tract in lipiodol group was significantly slighter than that in gelatin sponge group.Conclusion Partial splenic artery embolization with lipiodol should be employed for the treatment of hypersplenism when the patient is elder and the disease is accompanied by poor liver function,massive ascites,severe dysfunction of blood coagulation and serious portal hypertension.